DNA06 Lilly AD J4T-MC-OLAA

DNA06 Lilly AD J4T-MC-OLAA

Es posible que algunos contenidos no estén disponibles en español.

Purpose of this Study

In this study, people will be placed into one of two groups by chance. One group will receive the study medicine and the other group will receive a placebo, which has no active medicine. The study medicine is given one or two times through a small needle in the lower back into the area around the spinal cord. The medicine is designed to lower a protein that builds up in the brains of people with Alzheimer disease. Participants will stay in the research center for a few days during treatment so doctors can watch them closely. They will also need to have a study partner who can go with them to many of the study visits.

Who Can Participate?

Eligibility

The study is open to people age 50-85, with changes in memory that also have key markers for Alzheimer's Disease that can be identified during screening for the study.

Age Range

50-85

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

Description

The purpose is to study a new investigational drug in patients with early Alzheimer's Disease for safety.

Locations

Duke University Hospital

Visit Timing

Weekdays

Compensation

Yes

Spanish Materials Available

No

Study Details

Full Title

DNA06 - A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3954068 in Patients with Early Symptomatic Alzheimer?s Disease J4T-MC-OLAA

Principal Investigator

Shruti
Raja

Protocol Number

PRO00116407

NCT ID

NCT06297590

Phase

I

Enrollment Status

Open to Enrollment